The following new class structures were voted on by EphMRA/PBIRG in May/June 2020 and agreed in principle. These structures will now be used in the next part of the development process which is the detailed refinement of the rules.
Please note that these new class structures are provisional at this time. The 2021 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2020. The new structures then come into effect from the beginning of 2021.
Antineoplastics, protein kinase inhibitors
Idiopathic pulmonary fibrosis